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Accumulating evidence implicates heterogeneity
within cancer cell populations in the response to
stressful exposures, including drug treatments.
While modeling the acute response to various anti-
cancer agents in drug-sensitive human tumor cell
lines, we consistently detected a small subpopula-
tion of reversibly ‘‘drug-tolerant’’ cells. These cells
demonstrate >100-fold reduced drug sensitivity and
maintain viability via engagement of IGF-1 receptor
signaling and an altered chromatin state that requires
the histone demethylase RBP2/KDM5A/Jarid1A.
This drug-tolerant phenotype is transiently acquired
and relinquished at low frequency by individual cells
within the population, implicating the dynamic regu-
lation of phenotypic heterogeneity in drug tolerance.
The drug-tolerant subpopulation can be selectively
ablated by treatment with IGF-1 receptor inhibitors
or chromatin-modifying agents, potentially yielding
a therapeutic opportunity. Together, these findings
suggest that cancer cell populations employ a
dynamic survival strategy in which individual cells
transiently assume a reversibly drug-tolerant state
to protect the population from eradication by poten-
tially lethal exposures.INTRODUCTION
The relatively rapid acquisition of resistance to cancer drugs
remains a key obstacle to successful cancer therapy. Substan-
tial efforts to elucidate the molecular basis for such drug resis-
tance have revealed a variety of mechanisms, including drug
efflux, acquisition of drug binding-deficient mutants of the target,
and engagement of alternative survival pathways (Redmond
et al., 2008). Such mechanisms are generally believed to reflect
the existence of rare, stochastic, resistance-conferring geneticalterations within a tumor cell population that are selected during
drug treatment.
However, more recent findings have also revealed nonmuta-
tional mechanisms of drug resistance. For example, accumu-
lating evidence suggests that a small population of ‘‘cancer
stem cells’’ are intrinsically more refractory to the effects of a
variety of anticancer drugs, possibly via enhanced drug efflux
(Trumpp and Wiestler, 2008). Other studies have implicated
epigenetic mechanisms, suggesting that acquired drug resis-
tance does not necessarily require a stable heritable genetic
alteration (Glasspool et al., 2006). Indeed, an increasingly
observed phenomenon in cancer therapy is the so-called ‘‘re-
treatment response.’’ For example, some non-small cell lung
cancer (NSCLC) patients who respond well to treatment with
EGFR (epidermal growth factor receptor) tyrosine kinase inhibi-
tors (TKIs), and who later experience therapy failure, demon-
strate a second response to EGFR TKI re-treatment after a
‘‘drug holiday’’ (Kurata et al., 2004; Yano et al., 2005). Similar
re-treatment responses are well established for several other
anticancer agents (Cara and Tannock, 2001). Such findings
suggest that acquired resistance to cancer drugs may involve
a reversible ‘‘drug-tolerant’’ state, whose mechanistic basis
remains to be established. Furthermore, although specific resis-
tance-conferring mutations have indeed been identified in many
cancer patients demonstrating acquired drug resistance—
especially following treatment with selective TKIs—the relative
contribution of mutational and nonmutational mechanisms to
drug resistance and the role of tumor cell subpopulations remain
somewhat unclear.
While modeling the acute response to various anticancer
agents in several different drug-sensitive human cancer cell
lines, we consistently detected a small subpopulation of revers-
ibly ‘‘drug-tolerant’’ cells that maintain viability under conditions
where the vast majority of the cell population is rapidly killed.
Significantly, the emergence of these ‘‘drug-tolerant persisters’’
(DTPs) is observed even following expansion of single drug-
sensitive cancer cells, and they are detected at a frequency
much higher than would be expected due to mutational mecha-
nisms, implicating epigenetic regulation. Interestingly, we found
that this drug-tolerant phenotype is transiently acquired andCell 141, 69–80, April 2, 2010 ª2010 Elsevier Inc. 69
relinquished by individual cells within the population at a low
frequency, implicating the dynamic regulation of phenotypic
heterogeneity within a cancer cell population in drug resistance.
Taken altogether, our findings suggest that cancer cell popula-
tions exhibit reversible tolerance to drugs (and possibly other
stressful stimuli) via the maintenance of a phenotypically distinct
subpopulation of cells that can protect the population from
eradication by potentially lethal exposures.
RESULTS
Detection of a Drug-Tolerant Cancer Cell Subpopulation
While modeling the response to EGFR TKIs in an EGFR mutant
NSCLC-derived cell line (PC9) that demonstrates exquisite
EGFR TKI sensitivity, we observed that whereas the vastmajority
of cells are killed within a few days of exposure to a drug concen-
tration 100-fold greater than the IC50 value, a small fraction of
viable, largely quiescent cells could still be detected 9 days later
(Figures 1A and 1B). We refer to this subpopulation of cells as
‘‘drug-tolerant persisters’’ (DTPs), and they constitute 0.3%
of the starting PC9 population (Figure 1C). An analogous
subpopulation of DTPs was detected in several other cancer
cell lines with established drug sensitivity (Figure 1C). Similarly,
PC9 cells treated with the chemotherapy drug cisplatin also
yielded a small percentage of DTPs (not shown). Thus, a drug-
tolerant cancer cell subpopulation is broadly present within
tumor-derived cell lines.
Although DTPs are largely quiescent, approximately 20% of
them eventually resume normal proliferation in the presence of
drug, yielding colonies of cells referred to as ‘‘drug-tolerant
expanded persisters’’ (DTEPs), which can be propagated in
drug indefinitely (Figure 1B). To elucidate mechanisms under-
lying drug tolerance, the PC9 model was further explored. PC9-
derived DTEPs are 500-fold less drug sensitive than parental
PC9 cells (Figure 1D and Figure S1A available online) and can
be maintained indefinitely in erlotinib. In DTPs and DTEPs,
EGFR TKIs suppress EGFR kinase activity, indicating that drug
efflux does not account for their ability to survive treatment
(Figure 1E). PC9-derivedDTEPs retain the activatingEGFRmuta-
tion (Figure S1B), confirming that they did not arise from contam-
inating cells. Moreover, they have not acquired the EGFR T790M
mutation or MET gene amplification often associated with
acquired EGFR TKI resistance in NSCLC patients (Figure S1C
and data not shown), suggesting a distinct state of drug insensi-
tivity. The cell subpopulation demonstrating EGFR TKI tolerance
also exhibits reduced sensitivity to cisplatin, suggesting that the
observed drug tolerance is not pathway specific (Figure 1F).
Drug Tolerance Is Associated with Heterogeneity
within a Cancer Cell Population
Considering reported links between drug resistance and a
‘‘cancer stemcell’’ (CSC)phenotype,weexaminedCSCmarkers.
The putative CSC marker CD133 (Hemmati et al., 2003) is ex-
pressed in all DTPs, but only in approximately 2% of the parental
PC9 population (Figures 2A and 2B). DTPs were also highly
enriched (relative to parental PC9 cells) for expression of CD24,
another CSC marker in some settings (Vermeulen et al., 2008),
whereas another CSC marker, CD44, was equally represented70 Cell 141, 69–80, April 2, 2010 ª2010 Elsevier Inc.in both populations (Figure 2C and Figure S2A). Thus, DTPs
correspond to a small subpopulation of cancer cells that can
survive a high-concentration drug exposure that kills the vast
majority of cells, reflecting phenotypic heterogeneity within the
population. Significantly, DTEPs exhibit a CD133 and CD24
expression profile resembling parental PC9 cells (Figures S2B
and S2C), indicating that the conversion of DTPs (uniformly
CD133 positive) to DTEPs involves the re-establishment of
heterogeneity with respect to surface markers.
The Drug-Tolerant Phenotype Can Emerge De Novo
and Is Reversible
PC9 cells plated at low density yield clones with high efficiency
(50%–75%; not shown), and all tested single cell-derived
PC9 clones also yield DTPs and DTEPs at a frequency similar
to that of ‘‘uncloned’’ PC9 cells (Figures 2D and 1C), indicating
that the drug-tolerant subpopulation can emerge de novo at
low frequency from a largely drug-sensitive population. DTEPs
derived from clonal PC9 cells similarly demonstrate a low
percentage of CD133-positive cells, consistent with the sponta-
neous emergence of heterogeneity within the population
(Figure S2D). Similar findings were made in several of the other
tested cancer cell lines following clonal expansion from single
cells (data not shown).
The relatively high percentage of DTPs detected within these
various cancer cell populations (0.3%–5%; Figure 1C) is consis-
tent with a nonmutational, and therefore possibly reversible,
mechanism. Indeed, DTPs propagated in drug-free media
resume growth and rapidly reacquire EGFR TKI sensitivity (within
9 doublings) (Figure 2E). The same reversibility was seen with
DTPs isolated from several other tested cell line models (data
not shown). Notably, restoration of drug sensitivity in DTEPs
occurs abruptly around passage number 30 (Figures 2F and
2G), suggesting a temporal requirement to ‘‘unlock’’ the drug-
tolerant state. Proliferating DTEPs (from NSCLC, colorectal, or
melanoma cells) can be similarly drug-resensitized by drug-
free passaging, although it requires 90 doublings (or 20–30
passages) to restore sensitivity (Figures 2F and 2G and Figures
S2E, S2F, and S2G), suggesting that the drug-tolerant state
becomes stabilized over time.
Establishment of Drug Tolerance Requires
the Histone Demethylase KDM5A/RBP2/Jarid1A
To identify mechanisms underlying reversible drug tolerance, we
first undertook a comparative genome-wide gene expression
analysis of PC9 cells and PC9-derived DTPs and DTEPs. This
comparison revealed striking differences in the overall expres-
sion profiles of all three populations (not shown), and in DTEPs,
the distribution of differentially expressed genes along chromo-
somes was highly nonrandom, implicating global chromatin
changes in these cells (Figure 3A). Indeed, we observed differen-
tial nuclease sensitivity when comparing chromatin purified from
parental PC9 cells and PC9-derived DTEPs (Figure S3A), as well
as in DTEPs from colorectal cancer (Figure S3A) and melanoma
cells (not shown).
To identify proteins that potentially contribute to the chromatin
alterations required for drug tolerance, we focused on genes
whose expression was elevated in both DTPs and DTEPs.
Cell line DTP (%) S.D. (n=3)
PC9 0.27 0.21
PC9 cl.A 0.29 0.06
PC9 cl.B 0.17 0.05
PC9 cl.C 0.14 0.04
HCC827 5.46 1.07
M14 1.71 0.21
Colo 205 4.31 0.06
MDA-MB-175 v2 4.51 1.01
SKBR3 2.65 1.27
HCC1419 1.63 0.25
KATO II 4.81 0.11
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Figure 1. Detection of a Drug-Tolerant
Subpopulation of Cancer Cells
(A) Survival curve describing the viability of PC9
NSCLC cells treated with the indicated concen-
trations of the EGFR TKI gefitinib for 72 hr (similar
results were observed with erlotinib; Figure S1).
Each data point represents the average value
from four samples and is expressed as a per-
centage of surviving cells relative to untreated
controls. The dashed line corresponds to 50%
cell killing. The gray arrow indicates the concen-
tration of EGFR TKI (2 mM) used to generate
DTPs.
(B) PC9 cells were plated and left either untreated
(left) or treated with 2 mMerlotinib (ERL) for 9 days
(middle) or re-treated with drug every 3 days for
33 days (right). At the appropriate times, cells
were fixed and stained with Giemsa (upper
panel), or representative microscopic images
were photographed (middle panel). In the lower
panel, cells from the three different conditions
were replated at equal densities, and 20 hr
post-plating, cells were analyzed by FACS to
determine the percentage of cells in the indicated
cell-cycle phases. Data are based on two inde-
pendent experiments performed in duplicate.
(C) NSCLC-derived cell lines PC9 and HCC827
(EGFR mutation DE746-A750) were treated with
erlotinib (2 mM). The melanoma-derived cell line
M14 and the colorectal cancer-derived line
Colo-205 (BRAF mutation V600E) were treated
with the RAF kinase inhibitor AZ628 (2 mM). The
breast cancer cell lines MDA-MB175v2, SKBR3,
and HCC1419 (activated Her2) were treated with
Lapatinib (2 mM). The gastric cancer-derived cell
line KATO II (MET amplification) was treated with
the MET inhibitor PF-2341066 (1 mM). Single cell-
derived PC9 clones are designated PC9 cl.A, B,
C. Following 9 days of treatment (fresh drug was
added every 3 days), surviving DTPs were quanti-
fied. Each experiment was performed in triplicate.
(D) Survival curvesdescribingPC9cells andseveral
PC9-derivedDTEPclonesgeneratedbyselection in
2 mMgefitinib, then treatedwith the indicated gefiti-
nibconcentrationsfor72hr.Data representaverage
values determined from four identically treated
samples. Data are expressed as a percentage of
surviving cells relative to untreated controls. The
dashed line corresponds to 50% cell killing.
(E) (Upper panels) Lysates fromPC9cells treatedwith increasing concentrationsof erlotinib (0.01, 0.1, and 1mM) (left panel) or parental PC9cells andPC9-derivedDTPs
in 2 mMerlotinib (right panel) were analyzed by immunoblotting to detect phosphorylated EGFR (pEGFR) and total EGFR. (Lower panel) Lysates fromPC9 cells and ge-
fitinib-tolerant DTEPs after three passages in drug-freemedium, and subsequently treated for 2 hr with the indicated gefitinib concentrations, were analyzed by immu-
noblotting to detect phospho-EGFR and total EGFR.
(F) PC9 cells and PC9-derived DTEPs were either untreated (0) or treated with the indicated concentrations of cisplatin for 72 hr, after which cell numbers were deter-
mined. Each experiment was performed in triplicate, and the percentage of DTPs (relative to untreated controls) is presented. Error bars represent standard deviations
from the mean.
See also Figure S1.Among a small group of genes demonstrating elevated expres-
sion in both cell populations was a single gene that encodes a
chromatin-modifying enzyme, KDM5A/RBP2/Jarid1A (hereafter
referred to as KDM5A). KDM5A was initially discovered as a reti-
noblastoma-binding protein (Defeo-Jones et al., 1991; Fattaey
et al., 1993) and was found to exhibit histone H3K4-demethylat-
ing activity (Christensen et al., 2007; Iwase et al., 2007; Klose
et al., 2007; Secombe et al., 2007). Consistent with elevatedKDM5A in DTPs, they display reduced H3K4me3/2 (Figure 3B
and Figure S3B). To exclude the possibility that the reduced
histone methylation in DTPs reflects quiescence, we fraction-
ated PC9 cells after a brief exposure to EGFR TKI on the basis
of CD133 surface expression and determined that they are all
quiescent, as expected; however, only the drug-tolerant
CD133-positive fraction demonstrated reduced H3K4 methyla-
tion (Figure S3C).Cell 141, 69–80, April 2, 2010 ª2010 Elsevier Inc. 71
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Figure 2. Heterogeneity and Reversibility in
the Drug-Tolerant Cell Populations
(A) PC9 cells and PC9-derived DTPs were pro-
cessed for immunofluorescence using anti-CD133
and counterstainedwithHoechst to visualize nuclei.
Magnification, 203.
(B) Cell lysates from PC9 cells and PC9-derived
DTPs were analyzed by immunoblotting with
anti-CD133, and anti-GAPDH as loading control.
(C) PC9 cells and PC9-derived DTPs were labeled
with CD24 antibody conjugated to PE and a CD44
antibody conjugated to APC and analyzed by
FACS. Note the enrichment of cells with surface
expression of CD24 in DTPs (quantitation is shown
in Figure S2).
(D) Uncloned PC9 cells or cells from two different
single cell-derived PC9 clones (A and B) were
treated with 2 mM erlotinib for 33 days and then
Giemsa stained.
(E) Survival curves of PC9 cells and PC9-derived
DTPs following recovery and re-expansion in
drug-free medium and subsequent exposure to
the indicated erlotinib concentrations for 72 hr,
demonstrating the reversibility of drug tolerance.
Each data point represents the average value
determined from four samples. Data are ex-
pressed as percent surviving cells relative to
untreated controls. Error bars represent standard
deviations from the mean. The dashed line corre-
sponds to 50% cell killing.
(F) Survival curves of PC9 cells and a PC9-derived
DTEP line, GR7, after gefitinib withdrawal for the
indicated number of passages (P) and subsequent
exposure to the indicated gefitinib concentrations
for 72 hr. Each data point represents the average
value determined from four samples. Data are
expressed as percent surviving cells relative to
untreated controls. Error bars represent standard
deviations from the mean. The dashed line corre-
sponds to 50% cell killing.
(G) PC9 cells or PC9-derived DTEPs after gefitinib withdrawal for the indicated number of passages were either untreated or treated with 2 mM gefitinib (GEF) for
48 hr, after which cells were subjected to FACS analysis. Presented in the graph is the percentage of dying cells in the population (sub-G1 DNA content). Error
bars represent standard deviations from the mean from duplicate plates.
See also Figure S2.To test a specific requirement for KDM5A in drug tolerance, we
depleted KDM5A expression in PC9 cells using RNA interference
(Figure 3C and Figure S3D). In parental PC9 cells, KDM5A
knockdown did not detectably affect proliferation (Figure 3C
and Figure S3E) but significantly reduced the number of DTPs
as well as DTEPs upon EGFR TKI treatment (Figure 3D and
Figure S3F). Ablation of KDM5A also reduced the yield of DTEPs
following cisplatin treatment (Figure 3E). Furthermore, transient
expression of KDM5A in PC9 cells decreased the sensitivity of
the population to EGFR TKI treatment (Figure S3G). Together,
these observations suggest that the histone demethylase
KDM5A is required to establish a metastable chromatin state
that underlies reversible drug tolerance.
Drug-Tolerant Cancer Cells Are Selectively Ablated
by HDAC Inhibitors
The requirement for KDM5A in drug tolerance could yield a
therapeutic opportunity to prevent the development of resis-
tance to cancer drugs; however, pharmacologic inhibitors of72 Cell 141, 69–80, April 2, 2010 ª2010 Elsevier Inc.KDM5A have yet to be developed. KDM5A associates with
histone deacetylases (HDACs) (Klose et al., 2007; reviewed in
Cloos et al., 2008), and a yeast genetic screen to identify
suppressors of DNA damage revealed the KDM5A ortholog
Msc1, which was found to promote reduced histone H3K9/K14
acetylation (Ahmed et al., 2004). Acetylation of histone H3K14
is substantially reduced in PC9-derived DTPs and DTEPs,
consistent with upregulation of KDM5A and altered HDAC
activity in the drug-tolerant subpopulation (Figure 4A). We there-
fore reasoned that HDAC inhibition might phenocopy KDM5A
knockdown. Indeed, trichostatin A (TSA), an inhibitor of class I/
II HDACs (reviewed in Bolden et al., 2006), caused the rapid
death of DTPs and DTEPs but did not detectably affect parental
PC9 cells or TKI resensitized DTEPs (Figure 4B and Figures S4A
and S4B). Similarly, drug-tolerant populations of M14, Colo205,
HCC827, and HT-29 cancer cell lines also demonstrated TSA
hypersensitivity (Figures 4C and 4D and Figures S4C and S4D
and data not shown), suggesting a vulnerable HDAC-dependent
state within the drug-tolerant population in all cases (Figure 4E).
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Figure 3. Chromatin Alterations and
a Requirement for the KDM5A Histone
Demethylase in the Drug-Tolerant State
(A) Nonrandom expression differences between
PC9 cells and PC9-derived DTEPs, indicative of
global chromatin alterations. (Left panel) Non-
random chromosomal arrangement of differen-
tially upregulated and downregulated genes from
an array analysis of PC9 cells versus PC9-derived
DTEPs was revealed by counting the number of
neighboring differentially expressed genes that
are either both upregulated or both downregulated
(104 total pairs examined). The distribution on the
graph indicates the expected frequency of simi-
larly regulated neighboring genes, assuming no
relationship between expression status and chro-
mosomal configuration, and the arrow indicates
the observed number of neighboring genes that
are similarly regulated. The p value reflects the
statistical likelihood that the observed number is
different than the expected number. (Right panel)
Vertical ticks show the locations along different
chromosomes of genes differentially expressed
between PC9 cells and PC9-derived DTEPs
(tolerant to either gefitinib or erlotinib). Genes
whose expression is elevated in both the gefitinib-
and erlotinib-tolerant PC9 cells (relative to
untreated PC9) are shown above the horizontal
lines (which correspond to the chromosomes),
and genes whose expression is attenuated in
these cells are shown below the lines. Individual
genes are represented by vertical ticks of equal
width. Consequently, ticks that appear wide
represent a closely spaced cluster of genes.
(B) The left panel shows increased expression of
KDM5A in PC9-derived DTPs, relative to ERK1/2
as a loading control. The right panel shows the
decrease in histone H3K4 methylation (H3K4
me3/2) in PC9-derived DTPs compared to parental
PC9 cells either untreated () or treated for 20 hr
with 2 mM gefitinib (GEF), with total histone H3
and ERK1/2 serving as loading controls.
(C) (Upper panel) Immunoblot demonstrating reduced expression of KDM5A in PC9 cells lentivirally infected with shRNA targeting KDM5A (KDM5A k/d)
compared to PC9 cells infected with a control shRNA (C). (Lower panel) Cell-cycle profiles of these cells as assessed by FACS. Bar graphs represent two exper-
iments performed in duplicate. Error bars represent standard deviations from the mean.
(D) PC9 cells infected with control or KDM5A (KDM5A k/d) shRNAs were plated at equal density and treated with 2 mMgefitinib (GEF) for 30 days with media/drug
changes every 3 days. Surviving cells were counted (lower panel) or Giemsa stained and photographed (upper panel). Graphs represent two independent
experiments performed in duplicate. Error bars represent standard deviations from the mean.
(E) PC9 cells transduced with control or KDM5A (KDM5A k/d) shRNAs were plated at equal density and then treated with 2.5 mM cisplatin with media changes
every 2 days. Plates were Giemsa stained 12 days post-treatment.
See also Figure S3.An Altered DNA-Damage Response Underlies TSA
Sensitivity of Drug-Tolerant Cancer Cells
Although the effects of HDAC inhibition on gene transcription are
well established, accumulating evidence suggests that genomic
instability of cancer cells plays a role in their response to HDAC
inhibitors (Eot-Houllier et al., 2009). Significantly, the histone
variant H2AX (gH2AX) (Lavin, 2008), a marker of DNA damage,
is dramatically induced by TSA in PC9-derived DTPs and DTEPs
but not in parental PC9 cells (Figures 4F and 4G). TSA-induced
gH2AX was similarly observed in M14-derived DTEPs but not in
parental M14 melanoma cells (Figure S4E). gH2AX accumula-
tion can arise as an indirect consequence of DNA fragmentation.
However, whereas gH2AX in EGFR TKI-treated PC9 cells isindeed a consequence of DNA fragmentation, as indicated by
its attenuation in cells cotreated with a caspase inhibitor, the
increased gH2AX in TSA-treated DTEP cells is unaffected by
caspase inhibition, consistent with a distinct mechanism of
cell death in the TSA-treated drug-tolerant subpopulation
(Figure 4G). Furthermore, treatment of DTEPs with the check-
point override drug caffeine partially rescues these cells from
TSA-induced death and promotes S phase entry (Figure 4H),
suggesting a checkpoint-dependent mechanism of cell death
of DTEPs by TSA. Thus, the distinct chromatin state within
the drug-tolerant subpopulation renders these cells hypersensi-
tive to a TSA-induced DNA-damage response, resulting in cell
death.Cell 141, 69–80, April 2, 2010 ª2010 Elsevier Inc. 73
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Figure 4. Drug-Tolerant Cancer Cells Are
Sensitive to HDAC Inhibition
(A) (Upper panel) Immunoblot demonstrating
reduced H3K14 acetylation in PC9-derived DTPs
treated with 2 mM gefitinib. GAPDH serves as a
loading control. (Lower panel) Immunoblots to
detect histone H3K14 acetylation in PC9 cells and
PC9-derived DTEPs either untreated () or treated
for 24 hr with 1 mMof gefitinib (+GEF). Total histone
H3 (H3) and ERK1/2 serve as loading controls.
(B) (Upper panel) Sensitivity of PC9 cells and PC9-
derived DTPs to Trichostatin A (TSA). Cells were
plated at the same density and either untreated
or treated with the indicated TSA concentrations
for 20 hr, after which cells were subjected to
FACS analysis. Graphs indicate the percentage
of dying cells in the population (sub-G1 DNA
content), based on two independent experiments.
(Lower panel) TSA sensitivity of PC9 cells, PC9-
derived DTEPs, and resensitized DTEPs (cells
that reacquired sensitivity to EGFR TKIs following
30+ passages in drug-free medium). Cells were
either untreated or treated with the indicated
TSA concentrations for 24 hr, after which they
were subjected to FACS analysis. Presented in
the graph is the percentage of dying cells with
sub-G1 DNA content, based on three independent
experiments. Error bars represent standard devia-
tions from the mean.
(C) (Upper panel) TSA sensitivity of M14-derived
DTPs. Parental M14 melanoma cells and
M14-derived DTPs were plated at equal densities
and were either untreated (), treated with 2 mM
AZ628, or treated with 100 nM TSA for 36 hr, after
which they were subjected to FACS analysis. Indi-
cated in the graph is the percentage of cells that
display a sub-G1 DNA content indicative of apo-
ptotic cells. The values presented are the average
of two separate experiments. Error bars represent
standard deviations from the mean. (Lower panel)
TSA sensitivity of M14 and M14-derived DTEPs to
AZ628 and TSA. M14 cells or M14-derived DTEPs
were plated at equal density and were either
untreated (), treated with 2 mM AZ628, or treated
with 100 nM TSA, and then analyzed as described
above. The values presented are the average of
two separate experiments. Error bars represent
standard deviations from the mean.
(D) COLO 205 colorectal cancer cells or cisplatin-tolerant COLO 205 cells were plated at equal density and were either untreated () or treated with 50 nM TSA.
Thirty-six hours post-plating cells were subjected to FACS analysis. Indicated in the graph is the percentage of cell with a sub-G1 DNA content indicative of
apoptosis. The values presented are the average of two separate experiments. Error bars represent standard deviations from the mean.
(E) Model describing the emergence and reversibility of drug-tolerant cancer cells from a largely drug-sensitive population.
(F) Lysates from PC9-derived DTPs either untreated () or treated with 50 nM TSA for 20 hr were analyzed by immunoblotting using antibodies directed against
gH2AX and p44/42 ERK1/2 as a loading control.
(G) PC9 cells and PC9-derived DTEPs were either untreated (), treated for 24 hr with 1 mMgefitinib (+GEF), or treated with 50 nM TSA (+TSA), in the presence or
absence of the caspase inhibitor, Z-VAD, and lysates were analyzed by immunoblotting using antibodies directed against gH2AX. p44/42 ERK was immuno-
blotted as a loading control.
(H) PC9 cells and PC9-derived DTEPs were either untreated or treated with 2 mM caffeine, 75 nM TSA alone or, 75 nM TSA + 2 mM caffeine for 36 hr, after which
cells were subjected to FACS analysis. Indicated on the plot is the percentage of cells displaying sub-G1 DNA content (apoptotic cells; top histogram) and the
percentage of cells in S phase (bottom histogram). Error bars represent standard deviations from the mean of three independent experiments.
See also Figure S4.Inhibition of HDAC Activity Prevents the Development
of Drug Resistance
The detection of a reversibly drug-tolerant state prompted us to
determine whether pharmacologic disruption of this potentially74 Cell 141, 69–80, April 2, 2010 ª2010 Elsevier Inc.‘‘intermediate’’ state could prevent acquired drug resistance.
We examined the ability of 13 putative anticancer compounds
to prevent the emergence of EGFR TKI-tolerant PC9 colonies
by cotreating cultures continuously with TKI and these additional
AB C
Figure 5. Preventing the Establishment of
Drug-Tolerant Clones
(A) PC9 cells were either untreated or treated
singly with the indicated pharmacological agents
for 6 days (top rows) or with erlotinib (ERL) alone
or the combination of the indicated pharmacolog-
ical agent with erlotinib for 33 days (bottom rows).
Fresh media with drugs were provided every
3 days. Following treatment, plates were fixed
and Giemsa stained. All experiments were per-
formed in triplicate and representative plates are
shown.
(B) Individual colonies were counted and the quan-
tified results were graphed. In some cases the
colonies were too numerous to count (indicated
as >500 colonies). Error bars represent standard
deviations from the mean of three independent
experiments.
(C) PC9 cells were either treated with 2 mM of erlo-
tinib (ERL) for 25 days or pretreated for 9 days with
20 nM of TSA and then treated with 2 mM of erloti-
nib for 25 days. In parallel, PC9 cells were also
treated continuously with 20 nM TSA for 25 days.
After 25 days, plates were fixed and Giemsa
stained. The experiment was performed in tripli-
cate and representative plates are shown.compounds. Among the tested compounds, four different HDAC
inhibitors (TSA, SAHA, MS-275, and Scriptaid) (Bolden et al.,
2006), as well as AEW541, a selective inhibitor of the insulin-
like growth factor 1 receptor (IGF-1R) kinase (Garcia-Echeverria
et al., 2004), virtually eliminated the emergence of DTEP clones,
whereas eight other tested agents had no detectable effect on
colony formation in the presence of erlotinib (Figures 5A and
5B). Importantly, none of these agents, when tested individually,
demonstrated any significant effects on the growth and survival
of parental PC9 cells (Figure 5A).
Significantly, HDAC inhibitors must be continuously present to
prevent EGFR TKI resistance. Thus, PC9 cells treated for 9 days
with TSA prior to erlotinib treatment still yield DTEPswhen TSA is
withdrawn, suggesting that drug-tolerant cells are continuously
replenished in the absence of agents that eliminate them
(Figure 5C). This is consistent with our finding that DTPs arise
de novo within single cell-derived drug-sensitive populations.
The ability of TSA cotreatment to disrupt DTEP formation was
extended to several additional cancer cell lines (Figures 6A and
6B and Figure S5), suggesting that an HDAC-dependent drug-
tolerant state is broadly relevant in the acute response of cancer
cell populations to a lethal drug exposure.Cell 141, 6IGF-1R Signaling Is Required
for the Emergence of Reversible
Drug Tolerance
As described above, among many tested
kinase inhibitors, only an IGF-1R inhibitor,
AEW541, could prevent the emergence
of EGFR TKI-tolerant DTEPs. IGF-1R
phosphorylation is indeed increased
specifically in PC9-derived DTPs (Fig-ure 7A). The IGF-1R signaling pathway is regulated at multiple
levels (expression of ligand, receptor, and IGF-binding proteins),
and we determined that IGFBP3 (IGF-binding protein 3) levels
were specifically upregulated in the drug-tolerant PC9 cells
(Figure 7A). Previous reports have demonstrated that IGFBP3
promotes IGF-1R signaling (Baege et al., 2004; Ernst and Rodan,
1990), suggesting a potential mechanism by which IGF-1R is
activated in the drug-tolerant cells. A similar analysis was
performed in a genetically engineered mouse tumor model
(Ji et al., 2006). Shortly after erlotinib treatment of transgenic
mice bearing EGFR mutant lung tumors, which results in rapid
tumor regression, the residual tumor material demonstrated
increased phospho-IGF-1R levels, relative to untreated tumors,
consistent with the emergence of an IGF-1R-dependent drug-
tolerant state in vivo (Figure 7B). Furthermore, AEW541 treat-
ment of DTPs completely suppressed IGF-1R phosphorylation
(Figure 7C), and cotreatment of parental PC9 cells with EGFR
TKI plus AEW541 prevented the emergence of DTPs, whereas
addition of the IGF-1R ligand IGF-1 to the culture media of
drug-naive PC9 cells increased the yield of DTPs (Figure 7D).
IGF-1R signaling is similarly required for the drug-tolerant
phenotype observed in other tested cancer cell lines. Thus,9–80, April 2, 2010 ª2010 Elsevier Inc. 75
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Figure 6. Inhibition of HDAC Activity
Disrupts Tolerance to a Variety of Cancer
Drugs
(A) The EGFRmutant NSCLC cell line NCI-HCC827
was either untreated or treated with TSA (50 nM
TSA), erlotinib (2 mM ERL), or erlotinib plus TSA
(2 mM ERL + 50 nM TSA). After 6 days, the
untreated and TSA-treated plates had reached
confluence and were Giemsa stained. The erlotinib
and erlotinib + TSA-treated plates were similarly
fixed and stained after 19 days of treatment.
BRAF mutant M14 melanoma cells were either
untreated, treated with TSA (100 nM TSA), treated
with AZ628 (2 mM AZ628), or treated with AZ628 +
TSA (2 mM AZ628 + 100 nM TSA). After 6 days, the
untreated and TSA-treated plates had reached
confluence and were Giemsa stained. The AZ628
and AZ628 + TSA treated plates were similarly
fixed and stained after 39 days of treatment. PC9
cells were either left untreated or treated with
TSA (20 nM TSA), cisplatin (2 mM CIS), or cisplatin
plus TSA (2 mMCIS + 20 nM TSA). After 6 days, the
untreated and TSA-treated plates had reached
confluence and were Giemsa stained. The CIS +
TSA treated plates were similarly fixed and stained
after 45 days of treatment. Drug treatments were
repeated every 3 days. The experiment was per-
formed in triplicate and representative stained
plates are shown.
(B) Quantification of the lower panels in (A) expressed as the number of drug-tolerant colonies observed, with erlotinib-, AZ628-, and cisplatin-only treated cells
shown in black and the combination of these drugs with TSA shown in gray. Error bars represent the standard deviation from the mean (n = 3).
See also Figure S5.drug-tolerant cells derived from cisplatin-treated PC9 cells, as
well as melanoma cells treated with the BRAF inhibitor, were
efficiently killed by AEW541 (Figures 7E and 7F). Together, these
results suggest that the viability of the DTP subpopulation
requires IGF-1R activation.
To determine whether IGF-1R-mediated drug tolerance
requires the chromatin-modifying activity of KDM5A, we exam-
ined the requirement for KDM5A in IGF-1R-mediated DTP
formation. Whereas exposing PC9 cells to IGF-1 increases the
yield of DTPs upon treatment with EGFR-TKI, this effect is
suppressed by KDM5A ablation (Figure 7G and Figure S6A).
Furthermore, IGF-1R inhibition partially restores the reduced
histone H3K4 methylation seen in DTPs (Figure 7H), suggesting
that IGF-1R signaling required for drug tolerance is mediated by
the histone-demethylating activity of KDM5A. Significantly,
IGF-1R inhibition leads to a substantial reduction in KDM5A
expression, suggesting a direct link between IGF-1R signaling
and KDM5A function (Figure 7I). When PC9 cells were cotreated
for several weeks with EGFR TKI plus AEW541, a very small
number of DTEPs eventually emerged, and these were found
to harbor EGFR T790M alleles, indicating that this model can
yield a clinically established genetic mechanism of drug resis-
tance. Significantly, the rare DTEPs that emerge following
cotreatment with EGFR TKI plus AEW541 are TSA insensitive
(Figure 7J) and do not demonstrate evidence of chromatin alter-
ations, as revealed in nuclease sensitivity assays (Figure S6A).
Taken together, these findings suggest that a transient chro-
matin state, dependent on IGF-1R signaling and engagement
of KDM5A activity, mediates the emergence of drug tolerance.76 Cell 141, 69–80, April 2, 2010 ª2010 Elsevier Inc.DISCUSSION
Our analysis implicates a reversible drug-tolerant state in the
acute response of cancer cell populations to a lethal drug expo-
sure. The collective findings reveal a subpopulation of cancer
cells that transiently exhibit a distinct phenotype characterized
by the engagement of IGF-1R activity, hypersensitivity to
HDAC inhibition, altered chromatin, and an intrinsic ability to
tolerate drug exposure, which does not involve drug efflux
(Figure S6B). Reversible drug tolerance appears to reflect
dynamic heterogeneity within a cancer cell population that can
be established even following the clonal expansion of single
drug-sensitive cells. Such phenotypic heterogeneity has been
observed in some clonally derived normal mammalian cells,
such as stem cells (Chang et al., 2008; Stewart et al., 2006),
and has been implicated in cancer cell fates following drug expo-
sure in culture (Cohen et al., 2008; Gascoigne and Taylor, 2008).
The ability of the drug-tolerant subpopulation to maintain
viability following an otherwise lethal drug exposure appears to
involve IGF-1R engagement. This was observed in several tested
cell line models, suggesting a potentially broad role for IGF-1R
signaling in drug tolerance. Notably, IGF-1R activation has
been linked to drug resistance and poor prognosis in several
cancer settings (reviewed in Casa et al., 2008; Pollak, 2008).
Furthermore, several published reports describing cell culture
models of acquired resistance to both TKIs and conventional
chemotherapy drugs have similarly demonstrated the activation
of IGF-1R in drug-resistant derivatives (Buck et al., 2008; Chak-
ravarti et al., 2002; Dallas et al., 2009; Eckstein et al., 2009).
A B C
D E
HGF
I J
Figure 7. IGF-1R Activity Is Required for
the Chromatin State in Drug-Tolerant Cells
(A) Immunoblot demonstrating phosphorylation of
IGF-1R and expression of IGFBP3 in DTPs versus
parental PC9 cells. Total IGF-1R is shown as a
loading control.
(B) Immunoblot of extracts from an erlotinib-
treated (or untreated) lung tumor from a transgenic
mouse expressing an activating EGFR mutant.
After 2 days of treatment, EGFR phosphorylation
is reduced, and phospho-IGFR is detected in
residual tumor material. ERK1/2 is shown as a
loading control.
(C) Immunoblot demonstrating reduced phos-
phorylation of IGF-1R following treatment with
1 mm of the IGF-1R inhibitor AEW541 for 2 hr.
ERK1/2 is used as a loading control.
(D) Photomicrographs of PC9-derived DTPs
following four rounds of treatment (12 days) with
1 mM gefitinib (GEF), 1 mM gefitinib plus 1 mM
AEW541, or 1 mM gefitinib plus 50 ng/ml human
IGF-1. Representative fields are shown.
(E) PC9 cells were treated with 2.5 mM cisplatin or
2.5 mM cisplatin in combination with 1 mM
AEW541. After 30 days the plates were Giemsa
stained. A representative example is shown.
(F) M14 melanoma cells were treated with 2 mM
AZ628 or 2 mM AZ628 in combination with 1 mM
AEW541 in triplicate. After 30 days cells were
counted and the bar graphs reflect the number of
remaining cells per dish. Error bars represent
standard deviations from the mean.
(G) PC9 cells and PC9 cells in which KDM5A was
stably depleted by shRNA (k/d) were either
untreated or treated with gefitinib (GEF) or gefitinib
plus IGF-1 for 48 hr and then analyzed by FACS to
determine the percentage of cells with a sub-G1
content (apoptotic). Graphs reflect the average of
two independent experiments performed in dupli-
cate. Error bars represent standard deviations
from the mean.
(H) Immunoblot of extracts from parental PC9 cells
or PC9-derived DTPs plated at equal density and
treated with 1 mM of AEW541 for 16 hr. Note that
H3K4me2 (dimethylated) levels increase upon
addition of AEW541 to PC9-derived DTPs.
(I) Immunoblot of lysates from PC9-derived DTPs either untreated or treated with 1 mM of AEW541 for 24 hr. ERK1/2 is shown as a loading control.
(J) PC9 cells, PC9-derived DTEPs (gefitinib-treated), or PC9-derived DTEPs (gefitinib- and AEW541-treated) were either untreated or treated with gefitinib (GEF)
or TSA for 48 hr and then BrdU labeled and analyzed by FACS to determine the percentage of cell with a sub-G1 content (apoptotic). Graphs reflect the average of
two independent experiments performed in duplicate. Error bars represent standard deviations from the mean.
See also Figure S6.Our findings also implicate a distinct chromatin state in the
maintenance of the drug-tolerant subpopulation, and the histone
demethylase KDM5A was identified as at least one chromatin-
modifying enzyme required to establish this state. Notably,
reduced methylation of H3K4 has been linked to poor prognosis
in cancer patients (Seligson et al., 2005). It is certainly possible
that additional chromatin-modifying enzymes contribute to
drug tolerance in various tumor contexts. Indeed, our findings
also suggest a role for decreased histone acetylation in this
process. Although the regulation of histone demethylase activity
is poorly understood (Lan et al., 2008), our results suggest a role
for IGF-1R signaling in modifying KDM5A activity, which at least
partly involves the suppression of KDM5A expression.A transiently maintained drug-tolerant state could provide
a mechanism that allows a small subpopulation of tumor cells
to withstand an initial onslaught of drug or other stressful stimuli
to enable their survival for a period of time until more permanent
resistance mechanisms can be established. This is highly
reminiscent of the properties of antibiotic-tolerant bacterial
subpopulations, also called ‘‘persisters,’’ which similarly exhibit
a transient ability to endure potentially lethal stresses (Balaban
et al., 2004; Dhar and McKinney, 2007). These are slower
growing cells, whose survival within a more rapidly proliferating
cell population is ensured by the fact that they can readily
revert to a non-persister state via epigenetic mechanisms.
Consequently, the ‘‘burden’’ of protecting the population fromCell 141, 69–80, April 2, 2010 ª2010 Elsevier Inc. 77
eradication is shared equally among all members of the popula-
tion (Lewis, 2007). Our findings suggest that a subpopulation of
drug-tolerant cancer cells may behave similarly, and that all of
the tumor cells in a population potentially have the ability to
stochastically acquire and relinquish this protective phenotype
at a low frequency. Our collective findings support a striking
analogy between bacterial and cancer cell-derived persisters;
thus, both populations reflect dynamic phenotypic heterogeneity
of a nongenetic nature, both exhibit intrinsic multidrug tolerance
that does not involve drug efflux, and upon drugwithdrawal, both
give rise to progeny that are as susceptible to drug exposure as
their ancestors. These similarities raise the possibility that a
tumor cell population invokes more ‘‘primitive’’ properties
associated with microbial populations to ensure survival.
Our findings suggest a more complex ‘‘pathway’’ to stable
genetically conferred resistance to cancer drugs than is implied
by the detection of specific drug resistance mutations in tumors.
Such mutations are generally thought to arise spontaneously at
low frequency in tumor cells prior to drug treatment and are
selected during treatment. However, our observations implicate
a multistep ‘‘process’’ (Figure S6B) mediated by metastable
drug-tolerant states associated with chromatin alterations.
Importantly, the proposed model is not incompatible with ‘‘pre-
existing’’ resistance-conferring mutations. Thus, although drug
resistance mutations, such as EGFR T790M, may be present in
rare tumor cells prior to EGFR TKI exposure, they might also
arise from reversibly drug-tolerant cells. Significantly, accumu-
lating evidence supports a role for stress-induced mutagenesis
as an adaptive mechanism both in bacteria and in cancer cells
(Galhardo et al., 2007), raising the possibility that an increased
mutagenesis rate within drug-tolerant cells leads to a greater
opportunity for drug resistance mutations to emerge.
The relationship between the reversibly drug-tolerant subpop-
ulation and cancer stem cells is potentially complex. Although
DTPs display markers associated with CSCs, their ability to
survive lethal drug exposure does not involve drug efflux, a prop-
erty attributed to at least some drug-resistant CSCs. Moreover,
during the transition of DTPs to DTEPs, CSC-specific markers
are lost, and yet both cell populations are equally drug insensi-
tive. Emerging studies of CSCs have clearly revealed their
reduced sensitivity to a variety of toxic exposures (Eyler and
Rich, 2008), and recent studies have demonstrated that expo-
sure of mouse tumors to certain chemotherapy drugs can cause
tumor regression yielding a population of drug-refractory cells
with CSC properties (Kang and Kang, 2007). Considered with
our studies, such findings point to a likely relationship between
a reversibly drug-tolerant cancer cell subpopulation and the
CSC subpopulation. However, this relationship appears to be
complex and certainly merits further exploration.
Reversible drug tolerance may account for accumulating clin-
ical reports demonstrating that cancer patients treated with a
variety of anticancer drugs can be successfully re-treated with
the same drug after a ‘‘drug holiday.’’ The detection of a distinct
chromatin state in drug-tolerant cancer cells and consequent
hypersensitivity to HDAC inhibitors potentially yields a thera-
peutic opportunity to prevent the development of stable drug
resistance. To test this possibility, we have recently initiated a
clinical study to examine the ability of combining a chromatin-78 Cell 141, 69–80, April 2, 2010 ª2010 Elsevier Inc.modifying agent with erlotinib in NSCLC patients. Although the
trial is not yet completed, the early clinical data indicate that
the inclusion of a chromatin-modifying agent can dramatically
improve clinical benefit in a subset of patients demonstrating
acquired TKI resistance (S.V.S. and J.S., unpublished data).
When considering that acquired drug resistance may involve
multiple distinct molecular mechanisms that arise independently
within the same patient, thereby complicating strategies to
overcome such resistance with a single rationally targeted agent,
the potential ability to prevent the development of resistance by
disrupting a drug-tolerant state is provocative. However, further
studies will certainly be required to establish the in vivo signifi-
cance of the cell culture findings, as well as to determine more
precisely the molecular mechanisms underlying reversible drug
tolerance.
EXPERIMENTAL PROCEDURES
Cell Survival Assays
3 3 104 cells were plated in each well of a 12-well cluster dish. Twenty-four
hours after plating, media were removed and replaced with media containing
drugs. Fresh media were replaced every 2 days until untreated cells reached
confluence.Media were then removed, and cells were washed with phosphate
buffered saline (PBS) and then fixed for 15 min with 4% formaldehyde in PBS.
Cells were then washed with PBS and stained with the fluorescent nucleic acid
stain, Syto60 (1 nM in PBS; Molecular Probes) for 15 min. Dye was removed,
cell monolayers were washed with PBS, and fluorescence quantitation was
carried out at 700 nm with an Odyssey Infrared Imager (Li-Cor Biosciences).
Each experiment was performed in quadruplicate.
Generation of Drug-Tolerant Persisters
Drug-sensitive cells were treated with the relevant drugs, at concentrations
exceeding 100 times the established IC50 values, for three rounds, with each
treatment lasting 72 hr. Viable cells remaining attached on the dish at the
end of the third round of drug treatment were considered to be DTPs and
were collected for analysis.
Generation of DTEPs
105 cells were plated in five 10 cm plates and allowed to adhere for 24 hr. Cells
were then treated with 2 mM gefitinib or 2.5 mM erlotinib (for PC9), 2.5 mM
cisplatin for Colo205, or 2 mMAZ628 for M14 and HT29. Fresh media-contain-
ing drug was replaced every 3 days until clones of drug-resistant cells ap-
peared. Approximately fifty clones per dish appeared after 30 days of drug
selection. Isolated clones were individually expanded in drug-containing
media. Where indicated, cells were withdrawn from drug for analysis, but
‘‘stock cultures’’ of DTEPs were maintained in drug. To assess the effect of
the various pharmacological agents on the generation of DTEPs following
exposure to targeted agents, 106 cells were plated in triplicate under the indi-
cated conditions. After 24 hr, the various indicated compounds were added to
culture medium and replenished every 3 days. On day 6, untreated cells and
cells treated with the individual pharmacological agents alone had reached
confluence and were fixed with 4% paraformaldehyde in PBS and stained
with Syto60. Treated cells were cultured for 33 days, after which plates were
fixed and stained as described above.
Cell Harvesting and Protein Analysis
Cell lysates were prepared in Laemmli sample buffer and analyzed by immu-
noblotting as described previously (McDermott et al., 2007).
Immunofluorescence
Immunofluorescence analysis of CD133 on cells plated on glass coverslips
was performed after fixing cells in 4% paraformaldehyde in PBS, as described
previously (Quinlan et al., 2008).
Mouse Tumor Studies
Bitransgenic CCSP-rtTA/Tet-op-EGFR del exon 19 mice with lung adenocar-
cinomas driven by EGFR were exposed to a doxycycline-containing diet for
8 to 12 weeks and subjected to magnetic resonance imaging (MRI) to docu-
ment tumor burden as described previously (Ji et al., 2006). Mice identified
with lung tumor burden were then treated with erlotinib at 50 mg/kg/day or
vehicle via gavage. Two hours after the second dose, mice were sacrificed
and the tumor nodules were grossly dissected. As per Dana-Farber Cancer
Institute Animal Care and Use Committee approval, all mice were housed in
a pathogen-free environment at the Harvard School of Public Health and
were handled in accordance with Good Animal Practice as defined by the
Office of Laboratory Animal Welfare.shRNA Studies
Lentivirus-mediated delivery of shRNAs directed against KDM5A was per-
formed as previously described (Rothenberg et al., 2008), using shRNA
constructs from the Broad Institute TRC consortium. KDM5A expression
constructs were from Addgene.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
six figures and can be found with this article online at doi:10.1016/j.cell.
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